Nautilus Biotechnology
Update in progressNAUT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nautilus Biotechnology is a development-stage life sciences company building a platform to quantify the proteome. The Nautilus Voyager Platform is an end-to-end system with instruments, reagents, consumables, and software for high-resolution imaging, integrated fluidics, and rapid processing of protein libraries to decode and quantify proteins in samples. It offers single-molecule library prep kits, flow cells, and affinity reagents. Partners include Genentech, Buck Institute, Allen Institute, Cornell, Qatar Foundation, and the Michael J. Fox Foundation. Seattle, founded 2016.
Company score
- Sentiment
- 0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.06
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Sujal M. Patel
- Founded2016
- Employees127
- Websitewww.nautilus.bio
Identifiers
- ISINUS63909J1088
- FIGIBBG00W7G4M12
- CUSIP63909J108
- CIK0001808805